Biotherapeutic manufacturers must move beyond traditional batch and fed-batch processing and look to adopt continuous approaches to increase dose production, reduce costs, and maintain consistent quality. Join a panel of experts from Repligen as we discuss how the lessons learned from monoclonal antibodies (mAbs) production can be applied to advanced therapeutic medicinal products (ATMPs) including gene therapies, cell therapies, nucleic acid-based therapies, oncolytics, vaccines, and exosomes. We will explore the high-impact innovations driving process efficiency in mAbs and vector-based therapeutics production today, from upstream process intensification and downstream chromatography and advanced TFF systems with integrated real-time process analytics, and how these solutions can streamline processes, ensuring higher productivity, scalability, affordability, and accessibility for the therapies of tomorrow.
Webinar Learning Objectives
Understand the innovative technologies and strategies that led to boosted mAbs productivity, reduced COGS, and improved quality.
Examine how scalable N perfusion and intensified fed-batch using N-1 perfusion in mAbs and viral vector production can lead to 3X improvements in space-time yield
Learn how to overcome the unique challenges of advanced therapeutics, ensuring higher productivity, scalability, and cost-effectiveness in ATMP manufacturing.
The panel will discuss topics about:
The complexity of the new biotherapeutics and industry demands.
The role of PI in emerging modalities
Automation and AI technology and predictive modeling
Where the future of bioprocessing will be in 5 years
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
